Faculty profile

Hong Chang

Back to faculty

ProfessorDepartment of Laboratory Medicine & PathobiologyUniversity of Toronto

Hong Chang

Professor

Department of Laboratory Medicine & Pathobiology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
31 publications in the last five years, latest in 2026.
Senior (last) author on 26 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

100

Publications

1,487

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Haematologica · 2026
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study.
Cancer · 2026
Putative Clonal Evolution in a PHF6-Mutant T/NK-Cell Lymphoproliferative Disorder With Selective Loss of a STAT5B-Mutant Subclone.
EJHaem · 2026 · senior author

All 100 publications

100 publications.

Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.

Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, Tien FM, Lyu TW, Tsai XC, Lin CC, Chang H, Ko BS, Chou WC, Röllig C, Russell N, Dillon R, Hou HA

Haematologica2026

DOI: 10.3324/haematol.2025.288081 PMID: 41742883

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study.

Yasin I, Stengel A, Shao H, Kaur A, Mason EF, Patwardhan PP, Bailey NG, Ghosh S, Inamdar KV, Patel AA, Pandiri M, Zhang J, Sojitra P, Tariq H, Pan Z, Wiredja D, Wang P, Tjota MY, Segal JP, Chang H, Sallman DA, Arber DA, Tefferi A, Badar T, Perry AM, Haferlach C, Lager AM, Venkataraman G

Cancer2026

DOI: 10.1002/cncr.70210 PMID: 41417597

Putative Clonal Evolution in a PHF6-Mutant T/NK-Cell Lymphoproliferative Disorder With Selective Loss of a STAT5B-Mutant Subclone.

Turingan MA, Wei C, Almokhtar N, Vijenthira A, Chang H

EJHaem2026Senior author

DOI: 10.1002/jha2.70303 PMID: 42093850

Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance.

Li H, Xia Q, Yu M, Lv Y, Xiao J, Guo X, Dong K, Zhou Y, Zhong L, Wang T, Wu W, Gan C, Li M, Xiao N, Wang Q, Chang H, He Y, Gong B

Science China. Life sciences2026

DOI: 10.1007/s11427-025-3227-0 PMID: 42101566

CD47 promotes myeloma cell growth through JAK-STAT3/MYC signalling and is targetable by ruxolitinib.

Faruq O, Iyer D, Wang P, Shrestha M, Wei C, Schimmer AD, Chang H

British journal of haematology2026Senior author

DOI: 10.1111/bjh.70736 PMID: 42601820

Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8.

Bahrami Hezaveh E, Turingan MA, Zhou Q, Wei C, Tierens A, Sibai H, Chang H

Hematological oncology2026Senior author

DOI: 10.1002/hon.70207 PMID: 42249770

Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort.

Wangulu C, Zhao D, Zhou Q, Wei C, Kumar R, Schimmer A, Chang H

Cancers20253 citationsSenior authorOpen Access

DOI: 10.3390/cancers17091405 PMID: 40361333

Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study.

Pandiri M, Stengel A, Zhang J, Wang P, Shao H, Velmurugan S, Jacob A, Symes E, Kaur A, Rojek A, Sojitra P, Wiredja D, Zhou Q, Chang H, Patil E, Patel JL, Patel AB, Menon M, Ghosh S, Wool GD, Arber DA, Pan Z, Findley A, Badar T, Tariq H, Sallman D, Bell RC, Perry A, Haferlach C, Fitzpatrick C, Venkataraman G

Journal of clinical pathology2025

DOI: 10.1136/jcp-2024-209954 PMID: 40571403

Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms.

Symes EO, Wang P, Sojitra P, Menon MP, Patel AA, Hasan F, Ghosh S, Roloff GW, Zhou Q, Findley A, Badar T, Zhang J, Tariq H, Chang H, Bell RC, Perry AM, Venkataraman G

British journal of haematology2025

DOI: 10.1111/bjh.19895 PMID: 39551719

Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion.

Shi S, Zhou Q, Zhao D, Zarif M, Wei C, Sibai H, Chang H

Leukemia research2025Senior author

DOI: 10.1016/j.leukres.2025.107665 PMID: 40020451

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Hong Chang

Research

Latest papers

Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with &#x2265;5% blasts: An International TP53 Investigators Network (iTiN) study.

Putative Clonal Evolution in a PHF6-Mutant T/NK-Cell Lymphoproliferative Disorder With Selective Loss of a STAT5B-Mutant Subclone.

Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance.

CD47 promotes myeloma cell growth through JAK-STAT3/MYC signalling and is targetable by ruxolitinib.

Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8.

Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort.

Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study.

Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms.

Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion.

Frequent collaborators

Qianghua Zhou

Mark Minden

Donna Reece

Cuihong Wei

Yan Chen

José-Mario Capo-Chichi

Paul Hamel

Aaron Schimmer

Rosemarie Tremblay-LeMay

A. Stewart

Suzanne Trudel

Eldad Zacksenhaus

Winnie Lo

Hassan Sibai

Christine Chen

David Grant

Nan Jiang

Jiong Yan

Kathryn Tinckam

Rumina Musani

Barbara Morash

Vikas Gupta

Guillaume Richard-Carpentier

Brett Houston

Ayman Al Habeeb

Michael Rauh

Donald Branch

William Muller

Shauna Wentzell

Cynthia Tsien

Rajat Kumar

Christine Cserti-Gazdewich

Adam Smith

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study.